Real-world non-interventional long-term post-authorisation safety study of ruxolitinib in myelofibrosis.

Fiorenza Barraco, Richard Greil (Co-author), Raoul Herbrecht, Burkhard Schmidt, Andreas Reiter, Wolfgang Willenbacher, Reinier Raymakers, Rüdiger Liersch, Monika Wroclawska, Robert Pack, Karin Burock, Divyadeep Karumanchi, Heinz Gisslinger

Research output: Contribution to journalOriginal Article (Journal)peer-review

20 Citations (Web of Science)
Original languageEnglish
Pages (from-to)764-774
JournalBRITISH JOURNAL OF HAEMATOLOGY
Volume191
Issue number5
DOIs
Publication statusPublished - 2020

Keywords

  • MYELOPROLIFERATIVE NEOPLASMS
  • AVAILABLE THERAPY
  • EXPANDED-ACCESS
  • PHASE 3B
  • EFFICACY
  • CLASSIFICATION
  • DIAGNOSIS
  • CRITERIA
  • JUMP

Cite this